文献速递间质性肺疾病

非特发性肺纤维化间质性肺疾病的蛋白质组学生存生物标志物

Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease.
PubMed 文献 · Am J Respir Crit Care Med · 2025-01-01

研究利用两个前瞻性队列(发现队列n=676,验证队列n=616)的血浆高通量蛋白质组数据,识别并验证与非IPF ILD 3年无移植生存相关的蛋白质。发现队列中2925种蛋白质有73种与TFS相关,44种在验证队列中保持关联,其中双调蛋白、整合素β6和角蛋白19关联最强。多数验证标志物在非IPF ILD各亚型中关联一致,通路分析发现与IPF共享及非IPF ILD独有的分子通路。

要点

  • 双调蛋白、整合素β6和角蛋白19是非IPF ILD 3年无移植生存的最强预后蛋白质标志物。
  • 44种蛋白质在发现和验证队列中均与3年无移植生存相关。
  • 多数验证标志物在非IPF ILD各亚型中关联一致,并发现非IPF ILD独有的分子通路。

核心结论

  • 在非IPF ILD中识别并验证了新的预后蛋白质生物标志物,多数在非IPF ILD亚型间关联一致。
  • 多数标志物和通路与IPF既往报道重叠,但部分为非IPF ILD独有,提示独特生物学参与进展性非IPF ILD。

研究设计与样本

  • 发现队列为加州大学和德州大学前瞻性注册研究血浆,n=676。
  • 验证队列为PRECISIONS多组学研究,n=616。
  • 采用多变量Cox比例风险回归识别与3年无移植生存相关的蛋白质,并经错误发现调整后进入验证队列测试。

主要发现

  • 发现队列检测2925种蛋白质,73种与3年无移植生存相关。
  • 验证队列中44种蛋白质保持与3年无移植生存的关联。
  • 关联最强的蛋白质为双调蛋白(HR 2.51,95%CI 2.07-3.04)、整合素β6(HR 2.46,95%CI 1.95-3.10)和角蛋白19(HR 1.70,95%CI 1.47-1.98)。
  • 除一种外,所有验证标志物在非IPF ILD亚型中与3年无移植生存的关联一致。
  • 通路分析识别出与IPF共享的若干分子通路及三种非IPF ILD独有通路。

关键数值与推荐

  • 双调蛋白HR 2.51(95%CI 2.07-3.04)。
  • 整合素β6 HR 2.46(95%CI 1.95-3.10)。
  • 角蛋白19 HR 1.70(95%CI 1.47-1.98)。

临床怎么用

  • 双调蛋白、整合素β6和角蛋白19可作为非IPF ILD 3年无移植生存的预后标志物候选。
  • 多数标志物在非IPF ILD亚型间关联一致,支持跨亚型风险分层应用潜力。
  • 非IPF ILD独有分子通路的发现提示需针对其独特生物学探索干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Although idiopathic pulmonary fibrosis (IPF) has been widely studied, progressive non-IPF interstitial lung disease (ILD) remains poorly understood. Objectives: To identify and validate proteomic biomarkers of non-IPF ILD survival. Methods: High-throughput proteomic data were generated using plasma collected as part of prospective registries at the universities of California and Texas (discovery cohort; n = 676) and in the PRECISIONS multiomic study (validation cohort; n = 616). Proteins associated with 3-year transplant-free survival (TFS) were identified using multivariable Cox proportional hazards regression, and those associated with TFS after adjustment for false discovery were advanced for validation cohort testing. Pathway analysis was performed to identify molecular pathways unique to non-IPF ILD and shared with IPF. Measurements and Main Results: Of 2,925 proteins tested in the discovery cohort, 73 were associated with TFS, with 44 showing sustained TFS association in the validation cohort. The top TFS-associated proteins were amphiregulin (hazard ratio [HR], 2.51; 95% confidence interval [CI], 2.07-3.04), integrin subunit-β6 (HR, 2.46; 95% CI, 1.95-3.10), and keratin 19 (HR, 1.70; 95% CI, 1.47-1.98). All but one validated biomarker showed consistent TFS association across non-IPF ILD subtypes. Pathway analysis identified several molecular pathways shared with IPF, together with three pathways unique to non-IPF ILD. Conclusions: We identified and validated novel prognostic protein biomarkers in non-IPF ILD, most of which showed consistent association across non-IPF ILD subtypes. Although most biomarkers and molecular pathways identified were previously linked to IPF, several were unique to non-IPF ILD, suggesting that unique biology may contribute to progressive non-IPF ILD.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Alqalyoobi S, Smith JA, Maddali MV, et al. Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease. Am J Respir Crit Care Med. 2025. PMID: 40208180. doi:10.1164/rccm.202407-1506OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。